Ruth Du Moulin, PhD
About Ruth Du Moulin, PhD
Ruth Du Moulin, PhD, serves as the Vice President of Medical Affairs at Inozyme Pharma, bringing extensive experience in medical affairs and communications from various pharmaceutical companies. Her career spans over two decades, with significant roles at organizations such as ARIAD Pharmaceuticals, Takeda Oncology, and Novo Nordisk.
Current Role at Inozyme Pharma
Ruth Du Moulin serves as the Vice President of Medical Affairs at Inozyme Pharma, a position she has held since 2023. In this role, she is responsible for overseeing medical strategies and operations, focusing on enhancing the company's medical affairs capabilities. Her work is based in Boston, Massachusetts, where she engages with both internal teams and external stakeholders to drive the company's objectives.
Previous Experience in Medical Affairs
Ruth Du Moulin has extensive experience in medical affairs, having held several key positions in the pharmaceutical industry. She was Vice President of Medical Affairs at Forma Therapeutics from 2020 to 2022 and at ARIAD Pharmaceuticals from 2010 to 2017. Additionally, she worked at Novo Nordisk and Takeda Oncology in similar roles, contributing to the development and execution of medical strategies and communications.
Educational Background
Ruth Du Moulin earned her PhD in Biochemistry from the University of Galway. This academic foundation has equipped her with the scientific knowledge and research skills necessary for her career in the pharmaceutical industry, particularly in medical affairs and communications.
Career History and Expertise
Ruth Du Moulin has a diverse career history that includes roles at various pharmaceutical companies. She started as a Senior Scientific Communications Associate at Eli Lilly and later worked at Pfizer as Head of Clinical Programming and Writing. Her career reflects a strong focus on elevating the value of medical affairs through digital capabilities and stakeholder engagement.
Research and Leadership Accomplishments
Throughout her career, Ruth Du Moulin has demonstrated a commitment to post-approval research and stakeholder engagement. She has successfully delivered New Drug Applications (NDAs) and has led full leadership of a business unit, showcasing her strategic capabilities in the medical affairs landscape.